<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="62966"><DrugName>StemEx</DrugName><DrugNamesKey><Name id="42903614">StemEx</Name></DrugNamesKey><DrugSynonyms><Name><Value>StemEx</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>carlecortemcel-L</Value></Name></DrugSynonyms><CompanyOriginator id="1052404">Gamida-Teva Joint Venture</CompanyOriginator><CompaniesSecondary><Company id="1052404">Gamida-Teva Joint Venture</Company><Company id="16005">Gamida Cell Ltd</Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="62966" type="Drug"><TargetEntity id="333589" type="siDrug">Carlecortemcel-L</TargetEntity></SourceEntity><SourceEntity id="1052404" type="Company"><TargetEntity id="5035526052" type="organizationId">Gamida Cell Teva Joint Venture Ltd</TargetEntity></SourceEntity><SourceEntity id="16005" type="Company"><TargetEntity id="4296875405" type="organizationId">Gamida Cell Ltd</TargetEntity></SourceEntity><SourceEntity id="20348" type="Company"><TargetEntity id="4295875158" type="organizationId">Teva Pharmaceutical Industries Ltd</TargetEntity></SourceEntity><SourceEntity id="2990" type="ciIndication"><TargetEntity id="10063581" type="MEDDRA"></TargetEntity><TargetEntity id="D033581" type="MeSH"></TargetEntity><TargetEntity id="-1019569811" type="omicsDisease"></TargetEntity><TargetEntity id="1863" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="53558" type="Action"><TargetEntity id="4891" type="Mechanism">Drugs Targeting Cancer Stem Cells</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="2990">Stem cell transplantation</Indication></IndicationsSecondary><ActionsSecondary><Action id="53558">Stem cell modulator</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="884">Haematopoietic stem cell therapy</Technology><Technology id="857">Allogenic stem cell therapy</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology></Technologies><LastModificationDate>2018-07-20T15:38:56.000Z</LastModificationDate><ChangeDateLast>2018-07-21T00:00:00.000Z</ChangeDateLast><AddedDate>2009-03-24T11:03:48.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="16005" linkType="Company"&gt;Gamida Cell&lt;/ulink&gt;  was presumed to be developing StemEx (carlecortemcel-L), a mixture of expanded and unexpanded donor cord blood stem cells,   for potential use in stem cell transplantation,    in leukemia and lymphoma patients [&lt;ulink linkID="994181" linkType="Reference"&gt;994181&lt;/ulink&gt;], [&lt;ulink linkID="1045945" linkType="Reference"&gt;1045945&lt;/ulink&gt;], [&lt;ulink linkID="1365732" linkType="Reference"&gt;1365732&lt;/ulink&gt;]. In October 2007, a phase II/III trial began [&lt;ulink linkID="994254" linkType="Reference"&gt;994254&lt;/ulink&gt;]; in April 2011, enrollment was ongoing in the phase III trial in the US, Europe and Israel [&lt;ulink linkID="1185529" linkType="Reference"&gt;1185529&lt;/ulink&gt;]; in February 2013, the trial met the primary endpoint [&lt;ulink linkID="1365732" linkType="Reference"&gt;1365732&lt;/ulink&gt;]; in July 2013, the FDA had advised the company to conduct another phase III trial [&lt;ulink linkID="1446503" linkType="Reference"&gt;1446503&lt;/ulink&gt;]; in June 2015, the trial completed [&lt;ulink linkID="994254" linkType="Reference"&gt;994254&lt;/ulink&gt;]. Since that time no further development by Gamida has been reported.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1052404" linkType="Company"&gt;Gamida-Teva Joint Venture&lt;/ulink&gt;  (a joint venture of Gamida Cell and &lt;ulink linkID="20348" linkType="Company"&gt;Teva&lt;/ulink&gt;) was developing the drug for the potential use in  stem cell transplantation    in leukemia and lymphoma patients [&lt;ulink linkID="994181" linkType="Reference"&gt;994181&lt;/ulink&gt;]. In May 2012, Gamida was seeking to outlicense the drug to a strategic partner  to join in global commercialization   [&lt;ulink linkID="1290940" linkType="Reference"&gt;1290940&lt;/ulink&gt;]. In December 2012, Teva announced that development of the drug had been discontinued and at that time, relationship discussions were ongoing with Gamida [&lt;ulink linkID="1350215" linkType="Reference"&gt;1350215&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In September 2009,  launch of StemEx was expected in 2011 [&lt;ulink linkID="1045945" linkType="Reference"&gt;1045945&lt;/ulink&gt;]; in April 2011, the launch was expected in 2013 [&lt;ulink linkID="1185529" linkType="Reference"&gt;1185529&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In July 2013, the company anticipated the launch of the drug in a couple of years [&lt;ulink linkID="1446503" linkType="Reference"&gt;1446503&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2013, the company planned to meet the US in  spring 2013, for the discussions on the regulatory pathway for marketing approvals	[&lt;ulink linkID="1402851" linkType="Reference"&gt;1402851&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2011, the company  planned to submit a BLA to the FDA in 2012   [&lt;ulink linkID="1207012" linkType="Reference"&gt;1207012&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2010, the FDA granted StemEx Fast Track designation for use as an alternative to bone marrow transplants in  leukemia and lymphoma patients [&lt;ulink linkID="1109686" linkType="Reference"&gt;1109686&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2005,  StemEx had been granted  Orphan Drug status by the FDA   as a hematopoietic support in refractory hematological malignancies [&lt;ulink linkID="994181" linkType="Reference"&gt;994454&lt;/ulink&gt;]. In February 2010, the FDA awarded the drug Orphan status for use as a hematopoietic support in patients with myelodysplastic syndromes [&lt;ulink linkID="1219390" linkType="Reference"&gt;1219390&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In April 2013, the company planned to meet the EMA in  autumn 2013, for the discussions on the regulatory pathway for marketing approvals	[&lt;ulink linkID="1402851" linkType="Reference"&gt;1402851&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2011, the company planned to submit a MAA to the EMA  [&lt;ulink linkID="1207012" linkType="Reference"&gt;1207012&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2010, the EMA's Pediatric Committee  granted product specific waivers to the drug for birth to 17 years of age in all conditions [&lt;ulink linkID="1069528" linkType="Reference"&gt;1069528&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2005,  StemEx had been granted  orphan drug status by the  EMEA  as a hematopoietic support in refractory hematological malignancies [&lt;ulink linkID="994181" linkType="Reference"&gt;994454&lt;/ulink&gt;]. In January 2009, the COMP of the EMEA recommended Orphan Drug status be granted to allogeneic ex vivo expanded umbilical cord blood cells from Teva, presumed to be StemEx, for acute myeloid leukaemia [&lt;ulink linkID="975260" linkType="Reference"&gt;975260&lt;/ulink&gt;]. In June 2009, the COMP of the EMEA recommended Orphan Drug status be granted to the cells for Hodgkin lymphoma [&lt;ulink linkID="1016748" linkType="Reference"&gt;1016748&lt;/ulink&gt;]. In July 2009, the COMP of the EMEA recommended Orphan Drug status be granted to the cells for myelodysplastic syndrome and chronic myeloid leukemia (CML) [&lt;ulink linkID="1025435" linkType="Reference"&gt;1025435&lt;/ulink&gt;]. By November 2009, the cells had been granted  Orphan Drug status for myelodysplastic syndromes and CML [&lt;ulink linkID="1056283" linkType="Reference"&gt;1056283&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In July 2013, the company reported that the FDA had advised it to conduct a randomized, controlled phase III trial [&lt;ulink linkID="1446503" linkType="Reference"&gt;1446503&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2010, an investigator-led, open-label, parallel-assignment, non-randomized, double-arm, single-center,  safety/efficacy, pilot,  phase II study (&lt;ulink linkID="82958" linkType="Protocol"&gt;NCT01484470&lt;/ulink&gt;,  202041) led by &lt;ulink linkID="20610" linkType="Company"&gt;Loyola University&lt;/ulink&gt;, was ongoing in  elderly population with hematologic malignancies (n = 40) in the US. The study was expected to complete in January 2013. In July 2018, the trial was expected to complete in September 2018 (n = 18) [&lt;ulink linkID="1262156" linkType="Reference"&gt;1262156&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2006, FDA granted an  SPA for a phase II/III study [&lt;ulink linkID="994181" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="994455" linkType="Reference"&gt;994455&lt;/ulink&gt;]. In October 2007, a non-randomized, treatment, open-label, historical-control, single-group assignment, safety/efficacy phase II/III trial (&lt;ulink linkID="58226" linkType="Protocol"&gt;NCT00469729&lt;/ulink&gt;; ExCell) was initiated in subjects (n = 100) with leukemia and lymphoma in the US, Europe and Israel. The primary endpoint was to be overall 100-day mortality. The study was expected to complete in May 2012. The trial was ongoing March 2009 [&lt;ulink linkID="994254" linkType="Reference"&gt;994254&lt;/ulink&gt;].  In September 2009, the study was enrolling adolescent and adult patients in the US, Italy, Spain, Hungary and Israel [&lt;ulink linkID="1045945" linkType="Reference"&gt;1045945&lt;/ulink&gt;]. In February 2010, the data monitoring committee (DMC) recommended that the study continued enrolling patients, following a review of preliminary data. No safety concerns were raised. The next analysis of results was expected during the second quarter if 2010 [&lt;ulink linkID="1074295" linkType="Reference"&gt;1074295&lt;/ulink&gt;], [&lt;ulink linkID="1074314" linkType="Reference"&gt;1074314&lt;/ulink&gt;]. In April 2011, enrollment in the pivotal, registration trial  was ongoing in the US, Europe and Israel and by that time, the trial had been expected to be completed in 2011 [&lt;ulink linkID="1185529" linkType="Reference"&gt;1185529&lt;/ulink&gt;]. In July 2011,  the DMC  reviewed the data from the first 70 patients enrolled in the  trial   and has recommended the  continuation   of patient enrollment. At that time, enrollment was ongoing in   US, Europe, Israel and Spain [&lt;ulink linkID="1207012" linkType="Reference"&gt;1207012&lt;/ulink&gt;]. In February 2012, enrollment in the multicenter trial was completed and data were expected in the second half of 2012 [&lt;ulink linkID="1262395" linkType="Reference"&gt;1262395&lt;/ulink&gt;]. In May 2012, data from the international, pivotal registration trial were expected in the fourth quarter of 2012 [&lt;ulink linkID="1290940" linkType="Reference"&gt;1290940&lt;/ulink&gt;]. In February 2013, the trial met the primary endpoint with 15.8 and 25.4% mortality rate in StemEx and control groups, respectively. At that time,  full data were expected in 'few weeks' [&lt;ulink linkID="1365732" linkType="Reference"&gt;1365732&lt;/ulink&gt;]. In April 2013, data from the multicenter, multi-national, historical cohort-controlled 101-patient study were reported. Data demonstrated an improvement in the survival at 100 days post transplantation. Increase in the number of patients with early hematopoietic recovery were observed. Lower neutrophil engraftment failure rates were observed in the StemEx group (cumulative incidence 8.1%) compared to control group (cumulative incidence 14.5%; p = 0.086). No statistically significant survival advantage was reported by day 180 with mortality of 32.7 and 34.7% in the StemEx and control group, respectively (p = 0.39) [&lt;ulink linkID="1402851" linkType="Reference"&gt;1402851&lt;/ulink&gt;].  In December 2013,  similar data were presented at the  55th ASH Meeting in New Orleans, LA [&lt;ulink linkID="1503359" linkType="Reference"&gt;1503359&lt;/ulink&gt;]. The trial completed in June 2015 [&lt;ulink linkID="994254" linkType="Reference"&gt;994254&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2009, a phase I, single-center study indicated that treatment may lead to improved outcomes in large-sized transplant patients [&lt;ulink linkID="1050312" linkType="Reference"&gt;1050312&lt;/ulink&gt;], [&lt;ulink linkID="1050616" linkType="Reference"&gt;1050616&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 2002, a phase I/II trial was initiated; it completed patient enrollment in August 2004 [&lt;ulink linkID="994452" linkType="Reference"&gt;994452&lt;/ulink&gt;]. In  November 2004,  preliminary results suggested that the treatment was safe  [&lt;ulink linkID="994452" linkType="Reference"&gt;994452&lt;/ulink&gt;]. In May 2008, data from the safety and feasibility trial were published. Transplantation with ex vivo expanded cord blood cells was done in 10 patients. There was no instance of grade III-IV acute graft versus host disease, 100-day survival was 90% and 6-month survival was 60% [&lt;ulink linkID="1185567" linkType="Reference"&gt;1185567&lt;/ulink&gt;], [&lt;ulink linkID="1185529" linkType="Reference"&gt;1185529&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 2009, the EMEA's Pediatric Committee (PDCO) adopted an opinion on the refusal of a pediatric investigation plan and waiver for one subset of pediatric patients on the grounds that the therapy did not represent a significant advantage over existing treatments. The PDCO granted a product-specific waiver for all other pediatric subsets on the same grounds [&lt;ulink linkID="1060120" linkType="Reference"&gt;1060120&lt;/ulink&gt;], [&lt;ulink linkID="1069083" linkType="Reference"&gt;1069083&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;StemEx is used for the treatment of critical hematological diseases including leukemia and lymphoma in individuals  who can not find a matched bone marrow donor and are in need of a transplant [&lt;ulink linkID="994181" linkType="Reference"&gt;994181&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2008, Gamida signed an agreement with &lt;ulink linkID="14109" linkType="Company"&gt;Amgen&lt;/ulink&gt; to  use Amgen's proprietary cytokines in manufacturing StemEx [&lt;ulink linkID="994181" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="994455" linkType="Reference"&gt;994455&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2003, Gamida signed an option agreement with &lt;ulink linkID="20348" linkType="Company"&gt;&lt;/ulink&gt;Teva to develop StemEx. Teva was to make a decision after completion of phase I trials [&lt;ulink linkID="994181" linkType="Reference"&gt;994456&lt;/ulink&gt;]. In March 2005, Gamida and Teva had set up a joint venture to jointly develop StemEx [&lt;ulink linkID="996194" linkType="Reference"&gt;996194&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-11T00:00:00.000Z</StatusDate><Source id="1350215" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-11T00:00:00.000Z</StatusDate><Source id="1350215" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-11T00:00:00.000Z</StatusDate><Source id="1350215" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1052404">Gamida-Teva Joint Venture</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-11T00:00:00.000Z</StatusDate><Source id="1350215" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1052404">Gamida-Teva Joint Venture</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-11T00:00:00.000Z</StatusDate><Source id="1350215" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16005">Gamida Cell Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1052404">Gamida-Teva Joint Venture</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-08-01T00:00:00.000Z</StatusDate><Source id="994254" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-08-01T00:00:00.000Z</StatusDate><Source id="994254" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1052404">Gamida-Teva Joint Venture</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-10-31T00:00:00.000Z</StatusDate><Source id="994181" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-10-31T00:00:00.000Z</StatusDate><Source id="994181" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-08-01T00:00:00.000Z</StatusDate><Source id="994254" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1052404">Gamida-Teva Joint Venture</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-08-01T00:00:00.000Z</StatusDate><Source id="994254" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16005">Gamida Cell Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-04T00:00:00.000Z</StatusDate><Source id="1365732" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1052404">Gamida-Teva Joint Venture</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-12-31T00:00:00.000Z</StatusDate><Source id="994452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2990">Stem cell transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-03-31T00:00:00.000Z</StatusDate><Source id="996194" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of myelodysplastic syndromes</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-13T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of acute lymphoblastic leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-13T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of chronic myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-13T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-13T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of Hodgkin’s lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-02-01T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of myelodysplastic syndromes</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of acute lymphoblastic leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of Hodgkin’s lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of chronic myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1052404">Gamida-Teva Joint Venture</OwnerCompany><Country id="US">US</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>For use as hematopoietic support in patients with chronic myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-02-01T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1052404">Gamida-Teva Joint Venture</OwnerCompany><Country id="US">US</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>For use as hematopoietic support in patients with myelodysplastic syndromes</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-02-01T00:00:00.000Z</MileStoneDate><Source id="1219390" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of myelodysplastic syndromes</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-10-08T00:00:00.000Z</MileStoneDate><Source id="1056283" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of chronic myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-10-08T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of Hodgkin’s lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-07-24T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of chronic myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-07-08T00:00:00.000Z</MileStoneDate><Source id="1025435" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of myelodysplastic syndromes</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-07-08T00:00:00.000Z</MileStoneDate><Source id="1025435" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of Hodgkin’s lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-06-04T00:00:00.000Z</MileStoneDate><Source id="1016748" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of acute lymphoblastic leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-02-27T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-02-27T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-01-07T00:00:00.000Z</MileStoneDate><Source id="975260" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16005">Gamida Cell Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>Treatment of acute lymphoblastic leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-01-07T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1052404">Gamida-Teva Joint Venture</OwnerCompany><Country id="US">US</Country><Indication id="2990">Stem cell transplantation</Indication><AwardedIndication>For use as hematopoietic support in patients with relapsed or refractory hematologic malignancies who are receiving high-dose therapy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-03-04T00:00:00.000Z</MileStoneDate><Source id="994454" type="PR"></Source></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="16005">Gamida Cell Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="122233" title="Teva and Gamida to establish joint venture for development of StemEx"></Deal><Deal id="167122" title="Equity investment of $35M in Gamida Cell, with an option to fully acquire "></Deal></Deals><PatentFamilies><PatentFamily id="2079820" number="WO-2010128510" title="Methods for selecting expanded stem cell populations"></PatentFamily><PatentFamily id="319267" number="WO-09940783" title="Method of controlling proliferation and differentiation of stem and progenitor cells."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gamida Cell Ltd" id="16005"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hadassah Medical Organization" id="16594"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>